The purpose of this study is to test new pharmacologic strategies for weight loss in patients with schizophrenia, a population for which no current weight-loss treatments have gained widespread use. The goal is to recruit overweight people with schizophrenia to participate in a 52-week double-blind, randomized study to assess the efficacy and safety of lorcaserin/metformin combination treatment, lorcaserin monotherapy, and placebo on weight, body composition, and measures of glucose and lipid metabolism.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide)
Psychiatry - NC Research Center
Eating, Nutrition, and Metabolism
Mental and Emotional Health